Cancer is largely asymptomatic in early stages and the mortality increases with late detection. I look at glycosylation changes in cancer to identify new biomarkers that can be used as diagnostic targets. We have a highly sensitive and fluoresent nanoparticle based technology that we use to develop diagnostic assays for early cancer detection. I have developed an ovarian cancer diagnostic test that shows improved performance in postmenopausal women and in early stage cases compared to conventional assays. This test is now in the commercialization phase with a local diagnostic Turku based company. During my PhD, I've also worked with identifying novel biomarkers for lung cancer diagnosis, that we are now in the process of patenting.